Southeast Asset Advisors LLC Acquires 9,600 Shares of Abbott Laboratories $ABT

Southeast Asset Advisors LLC boosted its holdings in Abbott Laboratories (NYSE:ABT) by 69.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,364 shares of the healthcare product maker’s stock after buying an additional 9,600 shares during the period. Southeast Asset Advisors LLC’s holdings in Abbott Laboratories were worth $3,129,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ABT. Brighton Jones LLC boosted its holdings in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after buying an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC boosted its position in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of Abbott Laboratories by 6.6% in the 2nd quarter. Nordea Investment Management AB now owns 310,456 shares of the healthcare product maker’s stock valued at $41,921,000 after buying an additional 19,282 shares during the period. Foster & Motley Inc. increased its position in shares of Abbott Laboratories by 10.7% in the 2nd quarter. Foster & Motley Inc. now owns 4,506 shares of the healthcare product maker’s stock valued at $613,000 after buying an additional 435 shares in the last quarter. Finally, United Bank raised its stake in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after buying an additional 2,001 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 1.0%

Abbott Laboratories stock opened at $112.63 on Monday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The firm has a 50-day moving average of $119.48 and a 200-day moving average of $126.39. The company has a market cap of $195.84 billion, a price-to-earnings ratio of 30.28, a P/E/G ratio of 1.79 and a beta of 0.75. Abbott Laboratories has a one year low of $105.27 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period last year, the company earned $1.34 earnings per share. The business’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Thursday, January 15th were given a $0.63 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend was Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories’s payout ratio is 67.74%.

Insider Activity

In other news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was acquired at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the purchase, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Evercore dropped their price target on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Piper Sandler dropped their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a report on Friday, January 23rd. Barclays lowered their price objective on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. BTIG Research cut their price objective on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Finally, Daiwa Securities Group reduced their target price on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $137.05.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.